Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma’s (SPL) antiviral nasal spray is now available for purchase by consumers in Europe via the company’s online store
- VIRALEZE is a broad spectrum antiviral nasal spray, which studies have shown can inactivate more than 99.9 per cent of coronavirus pathogens within one minute
- The product is already available online in the U.K. and through Lloyds Pharmacy’s 1400 stores, with the company now pursuing avenues to provide rapid access for VIRALEZE in India
- Starpharma shares are up 3.93 per cent, trading at $1.85
Starpharma’s (SPL) antiviral nasal spray is now available for purchase by consumers in Europe via the company’s online store.
VIRALEZE is a broad spectrum antiviral nasal spray which studies have shown can inactivate more than 99.9 per cent of coronavirus pathogens within one minute.
The product has also demonstrated potent antiviral activity against multiple strains of SARS-CoV-2, as well as other respiratory viruses, including cold viruses, influenza, respiratory syncytial virus and SARS.
The antiviral active in VIRALEZE works by irreversibly blocking SARS-CoV-2 ‘spike’ proteins from binding to human airway cells, forming a physical barrier to respiratory viruses in the nasal cavity. The product is said to have the ability to inactivate a virus either before or after exposure.
VIRALEZE is already available in the UK online and through Lloyds Pharmacy’s 1400 stores and is expected to be available via independent UK pharmacies later this month.
“We are delighted to be rolling out VIRALEZE in Europe following the UK launch,” said Starpharma CEO, Dr Jackie Fairley.
“The product has been very well received in the UK, and we hope that VIRALEZE will provide European consumers with added peace of mind.”
Starpharma says it is now pursuing avenues to provide rapid access to VIRALEZE in India, including opportunities for expedited registration and distribution in the region.
The company is also progressing regulatory activities for a number of markets, including Australia, with the intention to roll it out globally.
Starpharma shares are up 3.93 per cent, trading at $1.85 at 10:50 am AEST.
